Loading...
Please wait, while we are loading the content...
Similar Documents
Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients.
| Content Provider | Europe PMC |
|---|---|
| Author | He, Jingjing Guo, Yifei Zhang, Yao Han, Jiajia Chen, Jingwen Jia, Yidi Ma, Zhenxuan Wu, Jingwen Zhang, Shenyan Li, Fahong Mao, Richeng Zhang, Jiming |
| Copyright Year | 2023 |
| Abstract | PurposeThe study aims to evaluate the effectiveness of a tenofovir alafenamide fumarate (TAF) and pegylated interferon alfa (PegIFN-α) regimen compared to a tenofovir disoproxil fumarate (TDF) and PegIFN-α therapy in patients with chronic hepatitis B (CHB).Patients and MethodsPatients who were treated with PegIFN-α in combination with TAF or TDF were retrospectively enrolled. The primary outcome measured was the HBsAg loss rate. The rates of virological response, serological response for HBeAg, and normalization of alanine aminotransferase (ALT) were also calculated. The cumulative incidences of response rates were compared between the two groups using Kaplan–Meier analysis.ResultsA total of 114 patients were retrospectively enrolled in the study, with 33 receiving TAF plus PegIFN-α treatment and 81 receiving TDF plus PegIFN-α treatment. The HBsAg loss rate for the TAF plus PegIFN-α group was 15.2% at 24 weeks and 21.2% at 48 weeks, while the TDF plus PegIFN-α group had rates of 7.4% at 24 weeks and 12.3% at 48 weeks (P=0.204 at 24 weeks, P=0.228 at 48 weeks). In subgroup analysis of HBeAg positive patients, the TAF group had a higher HBsAg loss rate of 25% at week 48, compared to 3.8% in the TDF group (P=0.033). According to Kaplan–Meier analysis, the TAF plus PegIFN-α group achieved virological response more quickly than the TDF plus PegIFN-α group (p=0.013). There was no statistical difference in HBeAg serological rate or ALT normalization rate.ConclusionThere was no significant difference in the HBsAg loss between the two groups. However, subgroup analysis revealed that TAF plus PegIFN-α treatment had a higher HBsAg loss rate than TDF plus PegIFN-α treatment in HBeAg-positive patients. Additionally, TAF plus PegIFN-α treatment demonstrated better virological suppression for CHB patients. Therefore, TAF plus PegIFN-α treatment regimen is recommended for CHB patients who aim to achieve functional cure. |
| Page Count | 13 |
| Volume Number | 16 |
| PubMed Central reference number | PMC10290461 |
| PubMed reference number | 37361938 |
| Journal | Infection and Drug Resistance [Infect Drug Resist] |
| e-ISSN | 11786973 |
| DOI | 10.2147/IDR.S411183 |
| Language | English |
| Publisher | Dove |
| Publisher Date | 2023-06-20 |
| Access Restriction | Open |
| Rights License | This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). © 2023 He et al. |
| Subject Keyword | hepatitis B virus infection tenofovir alafenamide fumarate tenofovir disoproxil fumarate interferon functional cure combination therapy |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pharmacology (medical) Infectious Diseases Pharmacology |
